HF-158K1 is under clinical development by Hangzhou Gaotian Biological Medicine and currently in Phase I for Colon Cancer. According to GlobalData, Phase I drugs for Colon Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HF-158K1 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HF-158K1 overview

HF-158K1 is under development for the treatment of HER2 expressing solid tumors (breast, bladder, pancreatic, ovarian, stomach, colon, prostate, lung, uterine and cervical cancers). It is a is a doxorubicin liposome that is being developed based on immunoliposome drug composites (iLDC) lipid technology. It is administered through intravenous route.

Hangzhou Gaotian Biological Medicine overview

Hangzhou Gaotian Biological Medicine (Gaotian Biological Medicine) is a manufacturer of pharmaceutical products for treatment of tumor. Gaotian Biological Medicine is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of HF-158K1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.